Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
IMPAX LABORATORIES INC (IPXL)
|
Add to portfolio |
|
|
|
| Price: |
$18.30
| | Metrics |
| OS: |
73.8
|
M
| |
-842
|
% ROE
|
| Market cap: |
$1.35
|
B
| |
59
|
% ROIC
|
|
Net debt:
|
$1.16
|
B
| |
3.9
|
x Debt/EBITDA
|
|
EV:
|
$2.51
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$300
|
M
| |
8.4
|
x EV/EBITDA
|
|
EBIT
|
$199
|
M
| |
12.6
|
x EV/EBIT
|
| EPS |
($6.96)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 |
| Revenues | 775.8 | 824.4 | 860.5 | 596.0 | 511.5 | 581.7 | 512.9 | 879.5 |
| Revenue growth | -5.9% | -4.2% | 44.4% | 16.5% | -12.1% | 13.4% | -41.7% | 145.4% |
| Cost of goods sold | 535.1 | 486.9 | 500.8 | 280.5 | 312.2 | 299.1 | 254.6 | 340.2 |
| Gross profit | 240.7 | 337.5 | 359.7 | 315.5 | 199.3 | 282.6 | 258.3 | 539.3 |
| Gross margin | 31.0% | 40.9% | 41.8% | 52.9% | 39.0% | 48.6% | 50.4% | 61.3% |
| Selling, general and administrative | 216.3 | 201.8 | 201.3 | 139.4 | 120.3 | 108.5 | 68.5 | 53.3 |
| Research and development | 80.8 | 80.5 | 70.6 | 78.6 | 68.9 | 81.3 | 82.7 | 86.2 |
| EBITA | 349.9 | 111.0 | 173.6 | 102.8 | -6.4 | 101.8 | 99.6 | 393.3 |
| EBITA margin | 45.1% | 13.5% | 20.2% | 17.2% | -1.2% | 17.5% | 19.4% | 44.7% |
| Amortization of intangibles | 68.4 | 56.5 | 40.2 | 11.1 | | 18.8 | | |
| EBIT | 281.5 | 54.5 | 133.4 | 91.7 | -6.4 | 83.0 | 99.6 | 393.3 |
| EBIT margin | 36.3% | 6.6% | 15.5% | 15.4% | -1.2% | 14.3% | 19.4% | 44.7% |
| Pre-tax income | -451.0 | -576.3 | 59.4 | 90.6 | 146.9 | 83.3 | 98.1 | 393.9 |
| Income taxes | 18.3 | -104.3 | 20.4 | 33.2 | 45.7 | 27.4 | 32.6 | 143.5 |
| Tax rate | | 18.1% | 34.3% | 36.7% | 31.1% | 32.9% | 33.2% | 36.4% |
| Net income | -469.3 | -472.0 | 39.0 | 57.4 | 101.3 | 55.9 | 65.5 | 250.4 |
| Net margin | -60.5% | -57.3% | 4.5% | 9.6% | 19.8% | 9.6% | 12.8% | 28.5% |
| |
| Diluted EPS | ($6.53) | ($6.63) | $0.54 | $0.81 | $1.47 | $0.82 | $0.97 | $3.82 |
| Shares outstanding (diluted) | 71.9 | 71.1 | 72.0 | 70.5 | 68.7 | 68.4 | 67.3 | 65.6 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|